Published in final edited form as:

Bioorg Med Chem Lett. 2013 April 1; 23(7): 2048–2051. doi:10.1016/j.bmcl.2013.02.010.

Synthesis and Anti-Acetylcholinesterase Properties of Novel β - and γ -Substituted Alkoxy Organophosphonates

S. Kaleem Ahmed, Yamina Belabassi, Lakshmi Sankaranarayanan, Chih-Kai Chao, John M. Gerdes, and Charles M. Thompson*

^aDepartment of Biomedical and Pharmaceutical Sciences, The University of Montana, Missoula, MT 59812, USA

Abstract

Activated organophosphate (OP) insecticides and chemical agents inhibit acetylcholinesterase (AChE) to form OP-AChE adducts. Whereas the structure of the OP correlates with the rate of inhibition, the structure of the OP-AChE adduct influences the rate at which post-inhibitory reactivation or aging phenomena occurs. In this report, we prepared a panel of β -substituted ethoxy and γ -substituted propoxy phosphonoesters of the type $p\text{-NO}_2\text{PhO-P(X)(R)[(O(CH}_2)_n\text{Z}]$ (R = Me, Et; X = O, S; n = 2, 3; Z = halogen, OTs) and examined the inhibition of three AChEs by select structures in the panel. The β -fluoroethoxy methylphosphonate analog (R = Me, Z = F, n = 2) was the most potent anti-AChE compound comparable ($k_i \sim 6 \times 10^6 \text{ M}^{-1}\text{min}^{-1}$) to paraoxon against EEACH. Analogs with Z = Br, I, or OTs were weak inhibitors of the AChEs, and methyl phosphonates (R = Me) were more potent than the corresponding ethyl phosphonates (R = Et). As expected, analogs with a thionate linkage (P=S) were poor inhibitors of the AChEs.

Keywords

Organophosphates; Inhibition; Electric Eel AChE; Recombinant human AChE; Rat brain AChE

Organophosphate (OP) compounds (e.g., diazinon, parathion; Fig. 1; P=S) have been widely employed as insecticides in which their mode of toxic action first requires conversion to the more reactive P=O (oxon) form.^{1, 2} Conversely, OP compounds that contain the oxon functional group and possess a leaving group that is readily stabilized upon release (e.g., F⁻, CN⁻) are readily reactive and define the properties present in nerve agents like VX, sarin (GB) and soman (GD) (Fig. 1).^{3, 4}

The mechanism of toxicity of most highly reactive OPs results from the inhibition of acetylcholinesterase (AChE), specifically phosphorylating an active site serine to produce an OP-AChE adduct.^{1, 2, 4} Formation of OP-AChE adducts diminish or halt the hydrolysis of the neurotransmitter, acetylcholine (ACh) causing a surplus of ACh in the neuronal synapse that triggers overexcitation of nicotinic and muscarinic receptors leading to neurotoxic events. Once the OP-AChE adduct is formed it can undergo reactivation (restoration of activity) or aging, which is defined as loss of a phosphoester group leading to an oxyanion that is intractable to reactivation (Scheme 1).^{5–7}

© 2013 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1-406-243-4643; fax: +1-406-243-5227; charles.thompson@umontana.edu (CMThompson).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The reactivation of OP-AChE adducts occurs by nucleophilic displacement at phosphorus (by water, oximes), whereas aging is influenced by branching and/or inductive properties that favor cationic (proton-assisted) mechanisms. For example, dimethoxyphosphoryl-AChE ($R = CH_3$, $Y = OCH_3$) undergoes reactivation within 1–2 h (or minutes using oxime antidotes) and ages with a $t_{1/2} \sim 2$ –10 h. Conversely, OP-AChE adducts containing branched alkoxy groups like sarin ($R = CH(CH_3)_2$) or soman ($R = CH(CH_3)(C(CH_3)_3)$) undergo aging to the methyl phosphonate anion ($Y = CH_3$) in 3–6 h and 2–5 min, respectively, affording little chance for the OP-adducts to reactivate.⁸

When the OP-ester component attached to AChE is a small, unbranched alkoxy group ($R = CH_2CH_3$, $CH_2CH_2CH_3$), these adducts are known to reactivate slowly and do not undergo appreciable aging ($t_{1/2} \sim 36$ –48 h) suggesting that these OP-AChE adducts are relatively stable.⁹ Herein, we report the synthesis and anti-AChE activity of OP compounds designed to form analogs of these stable OP-AChE adducts, for example, $(ZCH_2CH_2O)(Y)P(O)$ -AChE and $(ZCH_2CH_2CH_2O)(Y)P(O)$ -AChE ($Y = CH_3$, CH_2CH_3) in which Z is a halogen or tosylate substituent. It was thought that these customized inhibitors would form OP-AChE adducts in which the Z-substituent is positioned to influence the adduct stability and post-inhibitory reaction pathways. Since there are no systematic reports that prepare AChE-reactive, organophosphate compounds containing β - or γ -substituent phosphoester groups, this study was aimed to identify useful synthetic strategies to these structure supported by preliminary enzymatic evidence demonstrating their potential as enzyme inhibitors.

The OP targets (**4** and **5**) were designed and synthesized (Scheme 2) to include a number of key features. To produce OPs with useful inhibitory properties, a *p*-nitrophenol ester was installed as a leaving group. To examine the role, if any, of the alkyl group on the inhibition mechanism, both methyl and ethyl phosphonates were considered as targets. Both phosphonothionate ($P=S$) and phosphonate oxon ($P=O$) analogs were prepared. Phosphonothionates are expected to be less reactive toward nucleophilic displacement than oxons, and therefore likely to be poor inhibitors of AChE.¹⁰ However, the thionate $P=S$ bond reduces reactivity at the phosphorus center allowing functional group transformations to more readily proceed elsewhere on the molecule. Substituted, ethoxy and *n*-propoxy phosphoester groups were considered to evaluate the ease of substituent installation and potentially examine the contribution of inductive effects on inhibition. Additionally, if certain alkoxy substituents (Z) are leaving groups, the alkylation of AChE residues residing in proximity to the active site serine will be examined in a future study. To this end, twenty novel OP structures were produced with the most notable variation occurring in the alkoxy β , γ -substituents as F, Br, I and OTs.

Compounds **4a–j** and **5a–j** were first synthesized (Scheme 2) starting from the corresponding phosphoryl chlorides **1a** ($R = CH_3$) and **1b** ($R = CH_3CH_2$). Reaction with *p*-nitrophenol (PNP) in base affords the bis(4-nitrophenoxy) alkylphosphonates (**2a–b**) in good yield 87–91%.¹¹ To convert **2a–b** to the 4-nitrophenyl, hydrogen alkylphosphonic acids, LiOH, NaOH, KOH, Ba(OH)₂, Ca(OH)₂ were examined. Most conditions formed the hydrolyzed diacids or mixtures of hydrolysis products¹¹ except LiOH (0.5 M aq.) with CH₃CN that led to monoesters **3a–b** in moderate yield 51–54%.¹²

Monoesters **3a–b** were converted to the target compounds **4a–j** by reaction of the corresponding haloalcohol or tosyl alcohol in the presence of a coupling reagent, dicyclohexylcarbodiimide (DCC) or benzotriazol-1-yl-oxytris-(dimethylamino)-phosphonium hexafluorophosphate (BOP•PF₆). Both coupling reactions were successful; however, the use of DCC afforded higher yields.¹³ Coupling of monoesters **3a–b** to the alcohols was also attempted using Mitsunobu conditions or water soluble carbodiimides,

however, neither worked.^{14, 15} Oxons **4a–j** were treated with Lawesson's reagent to form the corresponding phosphonothionates **5a–j** in 60–65% yield.¹⁶

A more straightforward route to the target OPs **4a–j** and **5a–j** was undertaken by attempting to directly introduce the Z substituent by nucleophilic displacement of a leaving group on the ester side chain (Scheme 3). For example, the bromoethyl ester **4c** was treated with silver tosylate to form **4f** in 48% yield. We next attempted to prepare the 2-fluoro derivative **4a** using tetrabutyl ammonium fluoride (TBAF; 1.0 M aq. THF; 10 min) and the yield was low (13%). We attributed this low product yield to competing nucleophilic substitution at phosphorus and formation of a P-F bond as confirmed by the appearance of a d_{F-P} in the ^{31}P ($J = 1074$ Hz). To circumvent the P-F bond formation problem, which results in a toxic product, we examined the TBAF reaction using the thionate (P=S) **5f** as starting material, which owing to stronger $p\pi-d\pi$ overlap, would be less reactive toward nucleophiles at phosphorus. When **5f** was treated with TBAF, fluoride ion preferably displaced the OTs leaving group rather than the *p*-nitrophenol ester moiety in 10 min to afford **5a** in 33% yield. This yield was acceptable because there was no evidence of P(S)-F bond formation. The β -fluoroethoxy thionate **5a** was treated with *m*-CPBA to obtain **4a** in 58% yield.^{17–19} In sum, nucleophilic displacement of a side chain leaving group (Z) works with phosphonothionates as substrates but poorly with phosphonates leading to the reaction occurring preferentially at phosphorus producing hazardous phosphonofluoridates. All compounds were characterized by 1H , ^{13}C , ^{31}P , ^{19}F NMRs and HRMS data.^{20–23}

Many of the new compounds were screened for their inhibitory potency against EEChE (Table 1), and five were assessed in detail for their anti-cholinesterase activity. Owing to variations in the inhibitor solubility and reactivity, the bimolecular inhibition constants (k_i) for select compounds were determined using two kinetic methods: (a) a set inhibitor concentration [I] incubated with AChE for various time points (time-dependent) and (b) variable [I] incubated with AChE and measured at a set time point (concentration-dependent²⁰) kinetics (Table 1). Compounds **4a** and **4b** differ only in the alkyl-P bond as methyl- and ethyl phosphonates, respectively, and were examined by concentration- and time-dependent methods. Compounds **4a**, **4c** and **4f** are all methyl phosphonates that vary in the β -ethyl substituent Z and were examined by concentration or time-dependent kinetics. Paraoxon was also examined as a control.

First, the difference between methyl- and ethyl phosphonates was examined. The fluoroethoxy methyl phosphonate **4a** was found to be a 30 to 100-fold better inhibitor of EEChE than the corresponding ethyl phosphonate **4b** as determined by both time- and concentration-dependent kinetic methods. The inhibitory potency of **4a** was $k_i \sim 5 \times 10^6$ M⁻¹ min⁻¹ toward EEChE, which is comparable to the highly potent inhibitor, paraoxon.

Changing from 2-fluoroethoxy **4a** to the 2-bromoethoxy methylphosphonate **4c** led to a 70-fold decrease in inhibitory potency. This large difference in inhibition is somewhat surprising in light of the relatively small inductive and steric differences between F and Br that would be expected. However, additional or unforeseen steric considerations that affect the inhibitory potency other than those indirectly influencing the phosphorus atom cannot be excluded.

Replacing halogen substituents with a tosylate **4f** afforded a 50-fold weaker inhibitor of EEChE than the corresponding fluoro analog **4a** but comparable to the bromo analog **4c**. This result suggests that the larger tosylate group did not adversely affect the inhibition of EEChE, whereas altering the phosphonate from methyl to ethyl played a significant role in reducing the reactivity at phosphorus.

None of the phosphonothionates (**5**: P=S) were inhibitors of EEChE ($k_i < 10^2 \text{ M}^{-1}\text{min}^{-1}$) except **5c** that blocked enzyme activity at only seven-fold less than that of the corresponding oxon (P=O) (**5**: P=S). Typically, oxons are 100-fold more potent anticholinesterases than the corresponding thionates.¹⁰

Since the methyl β -fluoroethoxy phosphonate **4a** results in an OP-AChE adduct that closely resembles inhibition by the nerve agent VX, the concentration- and time-dependent inhibition of two mammalian acetylcholinesterases, recombinant human and rat brain, was also examined. For comparison, the ethylphosphonate analog **4b** and paraoxon were also studied. In general, the methyl β -fluoroethoxyphosphonate **4a** was a marginally more potent an inhibitor of the mammalian enzymes than that of EEChE. As found for EEChE, compound **4a** was a 100-fold more potent inhibitor of rHChE than the ethyl analog **4b**. To our surprise, the methylphosphonate **4a** and ethyl phosphonate analog **4b** showed comparable inhibition values ($\sim 10^6 \text{ M}^{-1}\text{min}^{-1}$) against RBChE suggesting that this enzyme is less sensitive to the added occlusion and inductively electron-donating properties of the ethyl group at phosphorus. Compounds **4a** and **4b** were 25 to 100-fold less potent inhibitors of RBChE than paraoxon by their respective concentration-dependent analyses.

As noted, the $(\text{CH}_3)(\text{CH}_3\text{CH}_2\text{O})\text{P}(\text{O})$ -serine adduct neither reactivates nor ages rapidly, which may be due to a combination of inductive and steric effects that reduce reactivity at the phosphorus atom and also reduce the propensity to form cation-like intermediates thought to underscore the aging mechanism. Since the phosphorylation of AChE inhibition by compounds **4a**, **4b**, **4c**, **4f**, and **5c** occur with concomitant loss of the *p*-nitrophenoxy group, the resulting OP-AChE adducts closely resemble that formed from VX, namely, the $(\text{CH}_3)(\text{CH}_3\text{CH}_2\text{O})\text{P}(\text{O})$ -serine adduct, which differs only in the retained β -substituent.²² For example, reaction of AChE with **4a** results in phosphorylation at ser-200 to produce a (Me) $(\text{FCH}_2\text{CH}_2\text{O})\text{P}(\text{O})$ -serine adduct.

In summary, a series of β - and γ -substituted alkoxy methylphosphonates were successfully prepared. The synthetic pathway is highlighted by a new approach that allows selective nucleophilic displacement at a phosphoester side chain rather than at a reactive phosphorus center. The enzymatic analyses demonstrated that the β -fluoroethoxy analog **4a** was the best inhibitor of acetylcholinesterases of those tested, and comparable in strength to paraoxon. The kinetic analyses also revealed two noteworthy results. First, the size of the alkoxy group substituent does not adversely affect the inhibitor strength. Second, the phosphonothionate analog **5c** was shown to possess anti-cholinesterase activity whereas P=S structures are normally inactive. The data produced in this study now makes possible advanced studies to further elucidate the mechanism of reactivation and aging by alkylphosphonates bearing substituted esters.

Acknowledgments

This research was supported by R21 NS072079 (CMT/JMG), the Core Laboratory for Neuromolecular Production P30 NS055022 (CMT), and NS058229 (ATERIS Technologies LLC).

References and notes

1. Eto, M. Organophosphorus pesticides; organic and biological chemistry. Cleveland: CRC Press; 1974.
2. Fest, C.; Schmidt, KJ. The chemistry of organophosphorus pesticides; reactivity, synthesis, mode of action, toxicology. Berlin, New York: Springer Verlag; 1973.
3. United States Army Medical Research Institute of Chemical Defense. [accessed on 11/09/06] Nerve Agents, in Medical Management of Chemical Casualties Handbook. 21995. <http://www.fas.org/nuke/guide/usa/doctrine/army/mmch/NervAgnt.htm>

4. Sidell FR, Borak J. *Ann Emerg Med.* 1992; 21:865. [PubMed: 1610046]
5. Ballantyne, B.; Marrs, TC. *Clinical and experimental toxicology of organophosphates and carbamates.* Oxford; Boston: Butterworth Heinemann; 1992.
6. Bajgar J. *Adv Clin Chem.* 2004; 38:151. [PubMed: 15521192]
7. Bajgar J, Kuca K, Jun D, Bartosova L, Fusek J. *Curr Drug Metab.* 2007; 8:803. [PubMed: 18220560]
8. Luo C, Tong M, Maxwell DM, Saxena A. *Chem Biol Interact.* 2008; 175:261. [PubMed: 18555982]
9. Sidell FR, Groff WA. *Toxicol Appl Pharmacol.* 1974; 27:241. [PubMed: 4855029]
10. Thompson CM, Frick JA, Natke BC, Hansen LK. *Chem Res Toxicol.* 1989; 2:386. [PubMed: 2519728]
11. McWhirter C, Lund EA, Tanifum EA, Feng G, Sheikh QI, Hengge AC, Williams NH. *J Am Chem Soc.* 2008; 130:13673. [PubMed: 18798625]
12. Liao X, Anjaneyulu PS, Curley JF, Hsu M, Boehringer M, Caruthers MH, Piccirilli JA. *Biochemistry.* 2001; 40:10911. [PubMed: 11551186]
13. Campagne JM, Coste J, Jouin P. *J Org Chem.* 1995; 60:5214.
14. Campbell DA, Bermak JC. *J Org Chem.* 1994; 59:658.
15. Udodong UE, Hansen MM, Verral DE, Harkness AR, Grutsch JL, Miller WD, Astleford B. *Tetrahedron.* 2003; 59:2667.
16. Ozturk T, Ertas E, Mert O. *Chem Rev.* 2007; 107:5210. [PubMed: 17867708]
17. Arnone A, Pregnotato M, Resnati G, Terreni M. *J Org Chem.* 1997; 62:6401.
18. Chworo A, WoŹniak LA. *Tetrahedron Lett.* 1999; 40:9337.
19. Thompson CM, Suarez AI, Rodriguez OP. *Chem Res Toxicol.* 1996; 9:1325. [PubMed: 8951236]
20. Rosenfeld CA, Sultatos LG. *Toxicol Sci.* 2006; 90:460. [PubMed: 16403852]
21. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. *Biochem Pharmacol.* 1961; 7:88. [PubMed: 13726518]
22. Millard CB, Koellner G, Ordentlich A, Shafferman A, Silman I, Sussman JL. *J Am Chem Soc.* 1999; 121:9883.
23. *General procedure for synthesis of bis(4-nitrophenyl) alkylphosphonate (<>2a-b):* To the alkyl phosphonyl dichloride (11.3 mmol) was added 4-nitrophenol (22.5 mmol) in CH₂Cl₂ (20 mL). The mixture was cooled in an ice-water bath and triethylamine (TEA; 45.1 mmol) in dry CH₂Cl₂ (5 mL) was added drop wise with stirring. TEA-HCl formed as the mixture stirred for 4 h at rt whereupon the reaction mixture was poured into 100 mL of ice cold water and extracted with CH₂Cl₂ (2 × 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and the solvent removed to yield crude bis(4-nitrophenyl) alkylphosphonate that was purified on a short silica column using 3:7, ethyl acetate:hexanes. Bis(4-nitrophenyl) methylphosphonate (**2a**) isolated as a pale yellow solid (3.49 g, 91%); ¹H NMR (500 MHz, CDCl₃) δ/ppm 8.22 (d, *J* = 9.29 Hz, 4H), 7.37 (d, *J* = 9.29 Hz, 4H), 1.95 (d, *J* = 17.71 Hz, 3H); ¹³C NMR (500 MHz, CDCl₃) δ/ppm 154.53, 145.08, 125.88, 121.11, 12.62 (d, *J*_{CP} = 144.25 Hz); ³¹P NMR (500 MHz, CDCl₃) δ/ppm 25.34; HRMS Calcd for C₁₃H₁₁N₂O₇P 338.0304; Found 339.0307 [(M + H)⁺]. See: Ghanem E, Li Y, Xu C, Raushel FM. *Biochemistry.* 2007; 46:9032. [PubMed: 17630782]
24. *General procedure for the synthesis of 4-nitrophenyl hydrogen alkylphosphonates (3a-b):* To the bis(4-nitrophenyl) alkylphosphonate (7.4 mmol) in CH₃CN (28.8 mL) was added 0.5 M LiOH (28.8 mL) drop wise using a pressure equalizing funnel over 20 min and stirred at rt for 1 h. The CH₃CN was removed under reduced pressure, and the aqueous solution extracted with CH₂Cl₂ (3 × 250 mL) to remove *p*-nitrophenol. The aqueous phase was then acidified with 3 N HCl to pH 0.5 and extracted with CH₂Cl₂ (3 × 250 mL). The organic phases were combined, and concentrated to give a crude semisolid that was re-crystallized using 10% EtOAc, 90% *n*-pentane. 4-Nitrophenyl hydrogen methylphosphonate (**3a**) was isolated as a crystalline light brown solid (0.86 g, 54%); ¹H NMR (500 MHz, CDCl₃) δ/ppm 8.20 (d, *J* = 9.13 Hz, 2H), 7.32 (d, *J* = 9.16 Hz, 2H), 1.66 (d, *J* = 16.69 Hz, 3H); ¹³C NMR (500 MHz, CDCl₃) δ/ppm 154.76, 144.81, 125.70, 121.26, 12.53 (d, *J*_{CP} = 139.25 Hz); ³¹P NMR (500 MHz, CDCl₃) δ/ppm 31.14; HRMS Calcd for chemical formula C₇H₈NO₅P 217.0140; Found: 218.0188 [(M+H)⁺]. Ghanem E, Li Y, Xu C, Raushel FM. *Biochemistry.* 2007; 46:9032. [PubMed: 17630782]

25. *General procedure for the synthesis of 2/3- haloalkylnitrophenyl alkylphosphonates and 2-(methyl (4- nitrophenoxy)phosphoryloxy)ethyl-4-ethylbenzene sulfonate (4a-j)*: To 4-nitrophenyl hydrogen alkylphosphonate (0.5 mmol) in dry CH_2Cl_2 (5 mL) was added the 2/3-haloalcohol or 2-hydroxyethyl 4-methylbenzenesulfonate (0.5 mmol) and DCC (0.9 mmol) at rt with stirring for 24 h. The reaction mixture was filtered through filter paper to remove DCU, the filtrate diluted with CH_2Cl_2 (50 mL), washed with DI water (3×50 mL), and the CH_2Cl_2 layer dried (Na_2SO_4). Filtration of Na_2SO_4 and removal of the solvent yielded the crude product that was purified over silica using 6:4 EtOAc:hex to afford the product. *2-fluoroethyl 4-nitrophenyl methylphosphonate (4a)*; a colorless sticky mass (76.3 mg; 58%): ^1H NMR (500 MHz, CDCl_3) δ 8.85 (d, $J = 9.27$ Hz, 2H), 7.40 (d, $J = 9.27$ Hz, 2H), 4.50–4.67 (m, 2H), 4.24–4.47 (m, 2H), 1.75 (d, $J = 17.85$ Hz, 3H); ^{13}C NMR (500 MHz, CDCl_3) δ /ppm 155.14, 144.75, 125.89, 121.11, 82.72, 81.35, 12.21 (d, $J_{\text{CP}} = 144.15$ Hz); ^{31}P NMR (500 MHz, CDCl_3) δ /ppm 29.33; ^{19}F NMR (500 MHz, CDCl_3) δ /ppm –224.47; HRMS Calcd for chemical formula $\text{C}_9\text{H}_{11}\text{NFO}_5\text{P}$ 263.0359; Found: 264.0434 [(M + H) $^+$].
26. *General procedure for synthesis of O-2/3-haloalkyl O-4- nitrophenyl alkylphosphonothioates and 2-(methyl(4- nitrophenoxy)phosphorothioxyloxy)ethyl-4-methylbenzene sulfonate (5a-j)*: Compound **4a-j** (0.2 mmol) taken up in 3 mL of dry toluene was added Lawesson's reagent (0.1 mmol) and the reaction brought to reflux for 3 h after which the reaction mass was filtered, washed with 2 mL CHCl_3 , and the filtrate directly loaded on preparative TLC plate using 1:3, ethyl acetate:hexanes to obtain the pure product. *O-2-fluoroethyl-Op- nitrophenyl methylphosphonothioate (5a)*; isolated as a semisolid (35.7 mg; 64%): ^1H NMR (500 MHz, CDCl_3) δ 8.26 (d, $J = 9.27$ Hz, 2H), 7.34 (d, $J = 9.27$ Hz, 2H), 4.49–4.66 (m, 2H), 4.24–4.48 (m, 2H), 2.11 (d, $J = 15$ Hz, 3H); ^{13}C NMR (500 MHz, CDCl_3) δ 154.99, 145.01, 125.43, 122.41, 82.70, 81.33, 66.35, 22.67 (d, $J_{\text{CP}} = 460$ Hz); ^{31}P NMR (500 MHz, CDCl_3) δ 96.15; ^{19}F NMR (500 MHz, CDCl_3) δ –224.29; HRMS Calcd for $\text{C}_9\text{H}_{11}\text{FNO}_4\text{PS}$ 279.0130; Found 280.0128 [(M + H) $^+$].

Figure 1.
Representative OP insecticides and nerve agents.

Scheme 1.
OP-inhibition of AChE and subsequent reactivation and aging reactions.

Scheme 2.

(i) *p*-NO₂PhOH, Et₃N, CH₂Cl₂, 0 °C to rt, 4 h; (ii) 0.5 M LiOH, CH₃CN, rt, 1 h; (iii) Z(CH₂)_nOH, DCC or BOP•PF₆, CH₂Cl₂, rt, 24 h; (iv) Lawesson's reagent, toluene, 80 °C, 3h.

Scheme 3.

Alternate route to target organophosphates: (i) TsO^-Ag^+ , CH_3CN , 65 °C, 4 h; (ii) 1.0 M TBAF in THF, rt, 10 min; (iii) *m*-CPBA, CH_2Cl_2 , rt, 30 min.

Table 1Inhibition rate constants (k_i M⁻¹min⁻¹) for **4a**, **4b**, **4c**, **4f** and **5c** against EEChE, rHChE and RBChE.

Cmpd	Method	EEChE	rHChE	RBChE
4a	CD	5.90±0.15×10 ⁶	7.51±0.21×10 ⁶	6.11±0.25×10 ⁶
	TD	2.50±0.50×10 ⁶	1.40±0.59×10 ⁷	6.16±0.28×10 ⁶
4b	CD	5.52±0.09×10 ⁴	6.16±0.16×10 ⁴	1.16±0.06×10 ⁶
	TD	8.64±2.20×10 ⁴	1.02±0.05×10 ⁵	3.77±0.48×10 ⁶
4c	CD	8.11±0.29×10 ⁴	nd	nd
4f	TD	1.14±0.03×10 ⁵	nd	nd
5c	TD	1.17±0.14×10 ⁴	nd	nd
paraoxon	CD	1.96±0.05×10 ⁶	nd	1.58±0.22×10 ⁸
	TD			3.39±0.14×10 ⁷

EEChE: electric eel acetylcholinesterase; rHChE: recombinant human acetylcholinesterase; RBChE: rat brain acetylcholinesterase. All k_i values (mean ± SEM) were determined from 2–4 different experiments at 25 °C. nd: not determined. CD: concentration-dependent. TD: time-dependent. All rate constants (k_i) were determined by Ellman assay.²¹